Article Details

Plant-based biopharma firm iBio licenses novel antibody targeting regulatory T cells

Retrieved on: 2021-09-02 09:11:15

Tags for this article:

Click the tags to see associated articles and topics

Plant-based biopharma firm iBio licenses novel antibody targeting regulatory T cells. View article details on hiswai:

Excerpt

This monoclonal antibody [mAb] was initially developed on a traditional mammalian cell manufacturing platform but iBio plans to optimize and manufacture RTX-003 ...

Article found on: www.biopharma-reporter.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up